Opus Genetics (NASDAQ:IRD) Hits New 12-Month High Following Analyst Upgrade

Posted by George Bondi on Sep 11th, 2026

Opus Genetics, Inc. (NASDAQ:IRD – Get Free Report)’s share price hit a new 52-week high on Wednesday after Wedbush raised their price target on the stock from $10.00 to $13.00. Wedbush currently has an outperform rating on the stock. Opus Genetics traded as high as $6.55 and last traded at $6.8370, with a volume of 10921380 shares changing hands. The stock had previously closed at $4.34.

Several other research analysts have also recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Opus Genetics in a research note on Wednesday. Zacks Research raised shares of Opus Genetics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Oppenheimer increased their target price on shares of Opus Genetics from $10.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday. Chardan Capital raised their target price on shares of Opus Genetics from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Wall Street Zen upgraded shares of Opus Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Opus Genetics presently has an average rating of “Moderate Buy” and an average target price of $11.92.

Read Our Latest Stock Report on IRD

Insider Activity

In other Opus Genetics news, CEO George Magrath sold 9,475 shares of the business’s stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $27,951.25. Following the sale, the chief executive officer directly owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 28,000 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total transaction of $127,120.00. Following the completion of the sale, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at $2,525,942.50. The trade was a 4.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 57,331 shares of company stock valued at $213,749 in the last ninety days. Company insiders own 11.70% of the company’s stock.

More Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

Positive Sentiment: Encouraging gene-therapy results: Opus reported positive three- and six-month results from the low-dose cohort of its Phase 1/2 OPGx-BEST1 trial for inherited retinal disease. All five participants showed clinically meaningful visual-function improvement, while no serious adverse events or dose-limiting toxicities were observed. Opus Genetics Announces Positive Low Dose Cohort 1 Data
Positive Sentiment: Path toward pivotal testing: Following an FDA Type C meeting, regulators aligned with a potential pivotal endpoint involving retinal sensitivity and patient-reported outcomes. Opus expects to complete second-cohort dosing in the fourth quarter of 2026 and potentially begin Phase 3 dosing in 2027. Management also said its cash runway extends into 2029, reducing near-term financing risk. Opus Genetics Reports Positive OPGx-BEST1 Data
Positive Sentiment: Analyst support increased: Wedbush raised its price target to $13 from $10 and maintained an “outperform” rating. Oppenheimer raised its target to $20 from $10, while BTIG, Chardan Capital and HC Wainwright reaffirmed bullish ratings with targets ranging from $8 to $13. These targets imply substantial potential upside, although they remain dependent on clinical execution.
Positive Sentiment: Options activity signals optimism: Traders purchased 4,820 call options, approximately 681% above typical volume, suggesting increased speculative interest in further gains.
Neutral Sentiment: Analyst views are not unanimous: Coverage remains broadly bullish, but some analysts hold more cautious ratings, making the overall outlook supportive but mixed. Analysts’ Opinions Are Mixed on Opus Genetics
Negative Sentiment: Insider sale: CFO Robert Gagnon sold 28,000 shares worth about $127,120 to cover tax withholding tied to equity vesting. The transaction was relatively small and attributed to taxes, but could still be viewed as a modest negative signal.

Hedge Funds Weigh In On Opus Genetics

Several hedge funds have recently made changes to their positions in the business. Blair William & Co. IL boosted its holdings in Opus Genetics by 12.3% during the fourth quarter. Blair William & Co. IL now owns 27,466 shares of the company’s stock worth $55,000 after buying an additional 3,000 shares in the last quarter. Opaleye Management Inc. increased its holdings in shares of Opus Genetics by 0.4% in the second quarter. Opaleye Management Inc. now owns 1,125,000 shares of the company’s stock valued at $4,624,000 after buying an additional 5,000 shares in the last quarter. Seven Fleet Capital Management LP lifted its position in shares of Opus Genetics by 6.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 143,137 shares of the company’s stock valued at $588,000 after acquiring an additional 8,895 shares during the last quarter. Raymond James Financial Inc. lifted its position in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after acquiring an additional 11,000 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new stake in shares of Opus Genetics during the 2nd quarter worth $50,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

Opus Genetics Stock Performance

The firm has a market capitalization of $501.69 million, a P/E ratio of -4.50 and a beta of 0.58. The firm has a 50 day moving average price of $3.86 and a two-hundred day moving average price of $4.32.

Opus Genetics (NASDAQ:IRD – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $2.63 million. Equities research analysts forecast that Opus Genetics, Inc. will post -0.99 earnings per share for the current fiscal year.

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.